Switch theme
Sign up to access all valuation multiples
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
2009
n/a
LTM Revenue $256M
LTM EBITDA $92.7M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sinopep has a last 12-month revenue of $256M and a last 12-month EBITDA of $92.7M.
In the most recent fiscal year, Sinopep achieved revenue of $142M and an EBITDA of $44.7M.
Sinopep expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sinopep valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $142M | $231M | XXX | XXX | XXX |
| Gross Profit | $49.5M | $51.7M | XXX | XXX | XXX |
| Gross Margin | 35% | 22% | XXX | XXX | XXX |
| EBITDA | $44.7M | $85.5M | XXX | XXX | XXX |
| EBITDA Margin | 31% | 37% | XXX | XXX | XXX |
| Net Profit | $15.9M | $17.8M | XXX | XXX | XXX |
| Net Margin | 11% | 8% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sinopep's stock price is CNY 50 (or $7).
Sinopep has current market cap of CNY 11.0B (or $1.5B), and EV of CNY 11.7B (or $1.6B).
See Sinopep trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.5B | XXX | XXX | XXX | XXX | $0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sinopep has market cap of $1.5B and EV of $1.6B.
Sinopep's trades at 6.3x LTM EV/Revenue multiple, and 17.3x LTM EBITDA.
Analysts estimate Sinopep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sinopep and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 18.8x | XXX | XXX | XXX |
| P/E | 26.8x | XXX | XXX | XXX |
| P/E/Growth | 0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSinopep's NTM/LTM revenue growth is 40%
Sinopep's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Sinopep's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sinopep's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sinopep and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 62% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 91% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 77% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sinopep acquired XXX companies to date.
Last acquisition by Sinopep was XXXXXXXX, XXXXX XXXXX XXXXXX . Sinopep acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sinopep founded? | Sinopep was founded in 2009. |
| Where is Sinopep headquartered? | Sinopep is headquartered in China. |
| Is Sinopep publicy listed? | Yes, Sinopep is a public company listed on SHG. |
| What is the stock symbol of Sinopep? | Sinopep trades under 688076 ticker. |
| When did Sinopep go public? | Sinopep went public in 2021. |
| Who are competitors of Sinopep? | Similar companies to Sinopep include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Sinopep? | Sinopep's current market cap is $1.5B |
| What is the current revenue of Sinopep? | Sinopep's last 12-month revenue is $256M. |
| What is the current EBITDA of Sinopep? | Sinopep's last 12-month EBITDA is $92.7M. |
| What is the current EV/Revenue multiple of Sinopep? | Current revenue multiple of Sinopep is 6.3x. |
| What is the current EV/EBITDA multiple of Sinopep? | Current EBITDA multiple of Sinopep is 17.3x. |
| What is the current revenue growth of Sinopep? | Sinopep revenue growth between 2023 and 2024 was 62%. |
| Is Sinopep profitable? | Yes, Sinopep is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
